The issue and debate around communications with health care professionals is at its very essence, a conversation about ensuring physicians have the best possible data to effectively treat patients. In an op-ed published in Morning Consult, Dr. R. Doyle Stulting, co-founder of the Stulting Research Center and the Director of Corneal Disease & Research at Woolfson Eye Institute noted FDA’s outdated regulations in this space and how sharing the latest information, which can improve patient outcomes, has become an increasingly burdensome venture [for manufacturers]. This is despite recent court rulings in the Caronia and Amarin cases explicitly allowing biopharmaceutical companies to provide truthful and non-misleading communications to health care professionals. Unfortunately, the FDA continues to muddy the waters with unclear guidance and inconsistent actions.
Lung Cancer Awareness Month is an opportunity to celebrate the stories of survivors, raise awareness about the leading cause of cancer death and continue the search for innovative new treatments and cures.
Lung cancer is the leading cancer killer for both men and women in the U.S. according to the American Lung Association, and in 2015 alone, approximately 27 percent of all cancer deaths will be from lung cancer. With lung cancer being the leader cancer killer in both men and women in the U.S., it is important to recognize the innovation happening to treat this deadly disease.
We’ve spent some time talking about the importance of shopping around during Part D open enrollment, which is currently underway until December 7th, 2015. Existing Part D plan coverage and individual health needs change from year to year so now is the time to review options and find the plan that works best for you.
Today, I want to share a personal story to demonstrate how important it is to shop around for a Part D plan.
Value of Medicine: Insurers continue to attack medicines and make it difficult for patients to access the drugs prescribed by their doctors. One patient shares his story about the difficulties trying to access the right medicine, at the right time.
340b Spotlight: A new study from The New England Journal of Medicine finds many non-profit hospitals are failing to meet the Affordable Care Act’s charity care requirements. Learn more about the impact on patients and why additional charity care requirements for hospitals that participate in the 340B program should be considered.
HHS Pharmaceutical Forum: As the Department of Health and Human Services (HHS) hosts a forum on pharmaceutical innovation, access, affordability and better health today, here are six key facts we need to consider as we look at spending across the health care system.
Topics: Week in Review
Insurers’ attacks on medicines often fail to account for the value of a medicine brings to society, the health care system and individual patients. This is exactly what the nation’s health insurers did in a recent blog post about a class of innovative biologic drugs that has revolutionized care for patients with several autoimmune diseases, including those in rheumatology, dermatology and gastroenterology.
The following is just one voice on the value of these medicines, and what it means for patients to have access to the right medicine, at the right time.
For years my job has been to work with physicians, patients and other health advocates in state capitals across the South to promote public policies that will help folks who are struggling to get better coverage for the medicines they need to live healthier, more productive lives. I’ve been armed with facts and figures and good policy arguments and I know how to talk to lawmakers about why it is critical for patients to get the right treatments at the right time.
Then, four years ago, I learned more than I ever thought I would.
I, a relatively young person with no real history of health problems, was now a patient.
New data published in The New England Journal of Medicine shows that many non-profit hospitals are not meeting charity care requirements in the Affordable Care Act. These requirements were intended to help address concerns from critics who questioned whether non-profit hospitals were providing sufficient benefits to justify their tax-exempt status, which was valued at $24.6 billion in 2011. Past analysis of 340B hospitals, which must be non-profit, found that about one-quarter provide charity care that represents less than one percent of their total patient costs. Additionally, about two-thirds of 340B hospitals provided less charity care than the average for all hospitals—including for-profit hospitals. This new study suggests that one reason for the low rates of charity care at many 340B hospitals is that in 2012 only 44 percent of non-profit hospitals regularly notified patients that they might be eligible for free or reduced price care before the hospital started debt collection.
Tomorrow, the Department of Health and Human Services (HHS) will host a forum on pharmaceutical innovation, access, affordability and better health. We welcome the opportunity to discuss how we can ensure patients have access to the care and treatments they need without unnecessary barriers. And while discussions about cost are important, we need to look at spending across the health care system to find solutions that ensure access to high quality, patient-centered care and continue to encourage development of innovative, life-changing medicines.
This November, we are pleased to be celebrating the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation’s 50th anniversary, commemorating five decades of jumpstarting the careers of more than 2,200 young scientists through $80 million in grant and fellowship awards.
Following a record-breaking year in 2015 of $3.6 million in new grants and fellowships to 43 young scientists, the Foundation is set to award $3.5 million in 2016 to 43 additional researchers.
Awards from the Foundation come at a critical point in young scientists’ careers, when they are beginning to establish themselves in their respective fields. Grant and fellowship funds are often used to establish labs, conduct experiments and explore novel disease targets.
Without clinical trials, new medicines could not be approved and made available to the patients who need them. But beyond connecting patients to new treatments and potential cures for some of the most devastating and costly diseases is the significant economic activity that clinical trials drive in communities across the country.
Research In Your Backyard is a program, sponsored by PhRMA, that highlights the importance of clinical trials to patient health and how clinical trials play a significant role in spurring economic development across the country. Through the program and as an educational resource, PhRMA develops statewide reports and holds local events to highlight the number and type of clinical trials taking place in collaboration with the state’s university medical schools, clinical research centers and hospitals.
We’ve seen reports on the use of high deductibles that include prescription drugs in health insurance exchange plans and the burden they put on patients. A recent IMS Health report, Emergence and Impact of Pharmacy Deductibles: Implications for Patients in Commercial Health Plans, reveals that commercial health plans are also increasingly applying deductibles to prescription drug benefits. The report indicates this trend is expected to continue as the 2018 effective date for the excise tax on higher-cost health plans, also known as the “Cadillac Tax,” approaches. The report also suggests this trend could have a negative impact on health, since IMS found that patients with pharmacy deductibles have lower adherence to drug therapies and higher prescription abandonment rates than patients without pharmacy deductibles. These new findings show how the changing structure of commercial health insurance coverage could lead to long term problems for patients and the health system at large.